Inhibikase Therapeutics
IKT
54 hedge funds and large institutions have $89M invested in Inhibikase Therapeutics in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 15 reducing their positions, and 2 closing their positions.
300% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 2
13% more funds holding
Funds holding: 48 → 54 (+6)
7% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 15
0.43% more ownership
Funds ownership: 73.33% → 73.76% (+0.43%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
16% less capital invested
Capital invested by funds: $106M → $89M (-$17.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$601K |
| 2 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
+$217K |
| 3 |
State Street
Boston,
Massachusetts
|
+$190K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$169K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$139K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$585K |
| 2 |
Morgan Stanley
New York
|
-$75.6K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$66.6K |
| 4 |
LP
LMR Partners
London,
United Kingdom
|
-$60.6K |
| 5 |
Barclays
London,
United Kingdom
|
-$42.7K |
IKT Hedge Fund Activity: Q3 2025 in Review
54 of the 7,631 institutional investors tracked by Wall St. Rank reported a position in Inhibikase Therapeutics (IKT) for Q3 2025, worth a combined $89M — down 16% from $106M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new IKT positions and 2 closed out — a net gain of 6 holders — while 16 added to existing stakes and 15 trimmed.
The largest buyer was BlackRock, adding an estimated $601K. The largest seller was Susquehanna International Group, cutting an estimated $585K.
- 54 institutional investors held Inhibikase Therapeutics (IKT) as of Q3 2025, up from 48 in Q2 2025.
- Funds reported $89M of Inhibikase Therapeutics stock for Q3 2025, down 16% quarter-over-quarter.
- 8 funds opened new Inhibikase Therapeutics positions in Q3 2025 and 2 closed out, a net change of +6 holders.
- The largest Inhibikase Therapeutics buyer in Q3 2025 was BlackRock, an estimated $601K added.
- The largest Inhibikase Therapeutics seller in Q3 2025 was Susquehanna International Group, an estimated $585K sold.
Based on aggregated 13F filings for Q3 2025.